Bennett, M.D., Ph.D., of the Northwestern University Feinberg College of Medicine, Chicago, and co-workers examined the rate of VTE and loss of life associated with ESA administration for treatment of anemia among individuals with cancer by conducting a review of phase 3 trials. The experts identified 51 clinical trials with 13,611 patients to examine survival. Evaluation of the info indicated that the risk of death was considerably higher for sufferers with cancer who were treated with ESA vs. The control group. Venous thromboembolism was evaluated for 38 trials that included 8,172 patients.Peptide microarrays enable researchers and doctors to explore the protein world with pinpoint precision. We are pleased at the rate of technological innovation taking place inside our laboratories, claims Rene Schena, CEO and co-founder of Arrayit Corp. Our next-generation proteomics tools are complimentary to advances in solid stage DNA sequencing, checking exciting new frontiers in preliminary research and diagnostics. .. Clinical Data completes NDA submission for vilazodone Clinical Data, Inc. , today announced that the Company has submitted a New Drug Program to the U.S. Drug and Food Administration for vilazodone for the treating major depressive disorder . Vilazodone is a dual-acting powerful and selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist.